Bruce Power announces milestone in medical Lu-177 production

June 24, 2022, 12:01PMNuclear News
The new IPS installed in Bruce Power’s Unit 7 will produce Lu-177 for treating cancer. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.

To continue reading, log in or create a free account!

Related Articles

Alberta funds SMR study

September 27, 2023, 9:48AMNuclear News

Canada’s Alberta province is investing C$7 million (about $5.2 million) to help Cenovus Energy study how small modular reactors could be used in northern Alberta to decarbonize oil sands...